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Abstract. Visceral leishmaniasis (VL) is a neglected parasitic disease that is fatal if left untreated and is endemic in
eastern Sudan. We estimated the direct and indirect costs of treatment of VL from the perspective of the provider and
the household at three public hospitals in Gedaref State. The median total cost for one VL episode was estimated to be
US$450. Despite the free provision of VL drugs at public hospitals, households bore 53% of the total cost of VL with one
episode of VL representing 40% of the annual household income. More than 75% of households incurred catastrophic
out-of-pocket expenditures. The length of treatment of 30 days led to important costs for both health providers and
households. Alternative treatment regimens that reduce the duration of treatment are urgently needed.
INTRODUCTION
Visceral leishmaniasis (VL) is a neglected parasitic disease
endemic in many parts of East Africa, in particular in eastern
Sudan with important foci also found in South Sudan, Ethiopia,
Kenya, and Uganda. VL is caused by Leishmania donovani
and transmitted to humans through the bite of a female
phlebotomine sand fly. The disease, also known as kala-azar,
is systemic and results in the death of the infected individual if
treatment is not provided in time. Signs and symptoms of VL
include prolonged fever, fatigue and weakness, anemia, and
enlarged lymph nodes, spleen, and liver.1
The public health importance of VL in East Africa is
undervalued not least because of the limited knowledge on
the disease burden, including the socio-economic aspects of
the disease. In the Indian subcontinent (India, Nepal, and
Bangladesh) studies examining the financial and economic
burden of VL have led to a better understanding of the impact
and the financial consequences of VL illness at the individual
and household level.2–4 Other tropical neglected diseases,
in particular the helminthic infections, have been successful
in garnering international attention and funding by showing
the low cost of control interventions and their cost effective-
ness. However, to date, no studies on the costs of VL illness,
either from the household or the health care provider perspec-
tive, have been carried out in East Africa. Better cost data
would allow the use of economic evaluation as a tool to
inform policy decisions and could help to make the case for
increased investment and resource allocation in VL control
policies and programs.
Therefore, we carried out a costing study on VL in Gedaref
State in eastern Sudan. The aim of this study was to estimate
both the cost of providing VL diagnosis and treatment ser-
vices (i.e., health care provider perspective) and the cost to
patients and their family to access these services (i.e., house-
hold perspective).
MATERIALS ANDMETHODS
This study is part of a research project on the cost effective-
ness of treatment alternatives for VL in Sudan initiated by the
Leishmaniasis East Africa Platform (LEAP) and the Drugs
for Neglected Diseases Initiative (DNDi).
Study sites. The study was conducted in Gedaref State,
Sudan† between October 2009 and May 2011. Gedaref State
is located in eastern Sudan bordering Ethiopia and had an
estimated population of 1.35 million in 2008, representing
3.4% of the Sudanese population.5 Agriculture is the main
economic activity in the State with main products including
sorghum, sesame, millet, and peanuts. Gedaref State is the
main VL-endemic area in the country and recently experi-
enced an important increase in the number of reported VL
cases (deaths) from 2,792 (109) in 2006 to 5,050 (142) in 2010
(Gedaref State Ministry of Health, unpublished data). How-
ever, because many people do not have access to health ser-
vices, the true incidence and mortality of VL are probably
much higher6; it is estimated that about 20,000 VL cases occur
annually in Sudan. The number of cases is expected to rise
because of migration into endemic areas, climate change,
human immunodeficiency virus (HIV)/VL co-infection, and
the overall lack of efforts to control the disease.7
The public health care system in Sudan is organized across
three levels: the Federal Ministry of Health (FMOH), the
State Ministries of Health (SMOH), and the district level. The
delivery of health care also follows a three-tiered structure.
Primary health care units are the lowest tier followed by health
centers and then rural/community hospitals.8 The National
Malaria, Schistosomiasis and Leishmaniasis Administration
(NMSLA) of the FMOH is responsible for VL control activities
in Sudan. Currently, VL control activities consist only of
passive case detection and treatment at rural/community hos-
pitals. Because of the low level of human and financial
resources, VL treatment services are often provided in collab-
oration with private-not-for-profit partners, either through
existing health facilities (e.g., Kassab Hospital supported by
*Address correspondence to Filip Meheus, Health Economics Unit,
School of Public Health and Family Medicine, University of Cape
Town, Anzio Road, Observatory 7925, South Africa. E-mail: Filip
.Meheus@uct.ac.za
†Sudan here refers to North Sudan and excludes the Republic of
South Sudan that became an independent State in 2011.
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the Institute of Endemic Diseases [IEND] and DNDi) or by
establishing independent health facilities (e.g., Um-el-Kher
Hospital used to be operated by Me´decins sans Frontie`res
[MSF] and now by the Ministry of Health). Although there are
no routine VL prevention activities, MSF has been involved
in the distribution of bed nets in endemic areas since 1995.9,10
We purposefully selected three health facilities in Gedaref
State as study sites: a public rural hospital located in Doka,
the State’s second largest city; a rural hospital in Kassab and a
hospital in Bazora town. The hospital in Doka, funded by the
Ministry of Health (MoH), is the largest of the three facilities
and has a capacity of 82 beds. It is a referral hospital providing
a wide range of medical services including surgery and obstet-
rical services. Kassab Hospital has a capacity of 68 beds
and receives funding from both the MoH and DNDi. This
hospital, located between Doka and the State capital Gedaref,
mainly provides VL treatment services. Both Doka and
Kassab Hospitals cover the area between Rahad and Atbara
Rivers together with other rural hospitals in the same area.
Bazora Hospital is the smallest of the three facilities with a
capacity of 51 beds and covers the Rahad River Basin area. It
is operated by the MoH and also receives funds from the
World Health Organization.
Current VL case management in Sudan. Sodium stibo-
gluconate (SSG), a pentavalent antimony compound, is the
first-line treatment of VL in Sudan11 and is administered
intramuscularly on a daily basis for 30 days at a dosage of
20 mg/kg/day. Although widespread resistance to SSG has
been reported in the Indian subcontinent,12,13 the drug is still
effective in Sudan with a cure rate of 92%14–16 but has numer-
ous side effects including nausea, diarrhea, muscle pains,
arrhythmia, and pancreatitis. Other treatment options are
currently being evaluated.17 Diagnosis of VL is made with
either the rK39 rapid diagnostic dipstick test, the direct agglu-
tination test (DAT) and/or microscopic confirmation of the
parasite in lymph node or bone marrow aspirate.18,19 Both
diagnosis and treatment of VL are provided free of charge at
public facilities. Other medical and non-medical costs (regis-
tration fee, laboratory investigations, food) need to be paid
out-of-pocket by the patient. All patients diagnosed with VL
are admitted for the full duration of treatment to ensure
100% adherence and to monitor for side effects because
patients are usually high risk presenting with severe anemia
and malnutrition.20
Costing methodology. The costs of VL were assessed from
the perspective of the health care provider and the household.
Each perspective involved a different methodology and data
collection process described in more detail below (Table 1).
Costs from the provider perspective. The aim of the analysis
from the providers’ perspective was to estimate the cost of
inpatient care at the health facilities included in the study to
provide VL treatment of one episode of VL. We only consid-
ered the cost of inpatient care because patients are hospital-
ized for the full duration of treatment and are not managed on
an outpatient basis. Because of data constraints we faced at
the health facilities, we estimated the medical costs of VL care
(drugs, diagnosis, medical supplies, and laboratory investiga-
tions) separately from the cost of hospitalization by combin-
ing step-down cost accounting with an ingredients approach.
These methods have been frequently used in similar studies in
Africa (e.g., References 21–23). Cost estimations represented
economic costs whereby all goods and services were valued
including voluntary labor and donated or subsidized goods
and services24; all data were collected for the year 2008.
Table 1
Overview of costing methods used to estimate the unit cost of visceral leishmaniasis (VL) care and household costs in Sudan (2010) for one
VL episode
Perspective
Provider Household
Costs included Direct medical
costs of VL
treatment (drugs,
laboratory tests)*
Other recurrent
and capital costs
Direct medical
(registration, drugs,
laboratory. test)
and non-medical costs
(food, transportation*
Indirect costs, i.e.
productive
time losses
Estimation method Ingredient approach Step-down costing – Human capital
method
Data sources Review of 250
medical records of
VL patients†
Health facility
records and primary
data collection
Questionnaire‡ Questionnaire‡
Intermediary
outcome
Median medical
cost per patient (a)
“Hotel” unit cost
per inpatient day (b)
Median out-of-pocket
expenditures on VL
services (c)
Median loss of
income to the patient
and family members
caring for the patient (d)
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ} |ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
Final outcome (a) + [(b) + ALOS§] =Median cost of VL
care per VL episode
(b) + (d) =Median cost incurred by
households per VL episode
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
Median cost per episode of VL
*Medical goods and services charged to patients were excluded to avoid double counting with the analysis from the household perspective.
†Detailed medical records were only available at Kassab Hospital. Calculations on direct medical costs of VL treatment were only done at this hospital and assumed to be the same for the other
two hospitals.
‡Data from the household perspective was collected from Kassab and Bazora Hospitals. There were no patients attending Doka Hospital at the time of the study caused by a shortage of SSG.
§ALOS = average length of stay.
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The medical cost of VL care was calculated using the ingre-
dients approach, whereby the quantity of inputs used were
multiplied by their price, with data obtained from a random
retrospective sample of 250 medical records of patients that
attended Kassab Hospital in 2008. We retrieved information
on demographic characteristics, the date of admission and
discharge, and the amount of SSG, laboratory investigations,
and medical supplies patients received. This estimation was
only done at Kassab Hospital for lack of sufficiently detailed
medical records at the other two facilities. The price of
generic SSG (Albert David, India) was US$ 8.25 per 30 mL
vial of 100 mg/mL.25 The unit costs of VL diagnosis and other
laboratory investigations were also estimated using an ingre-
dients approach by observing resource use at the laboratory
of Kassab Hospital. The prices of medical and laboratory
supplies and equipment were obtained from specialized sup-
pliers in Khartoum. All items paid for by the patient were
excluded from this analysis to avoid double counting with the
data collected from the household perspective.
The step-down costing was used to allocate recurrent non-
medical and capital costs and calculate the unit cost per
inpatient day. This unit cost corresponded to the World Health
Organization (WHO) definition of a “hotel” unit cost, which
excluded the medical costs of VL care estimated with the
ingredients approach described previously.26 At each facility,
information on recurrent expenditures were obtained from the
financial records and consisted of aggregated data on admin-
istration costs (printing, stationary), vehicle running costs (fuel,
maintenance), maintenance of buildings, utilities (electricity
and water), etc. Personnel costs were not included in the
financial statements and were estimated by compiling a list
by department/unit of all staff by type and grade with their
monthly salary and allowances. Staff that worked on a volun-
tary basis or were paid by external partners were given the
same salary as personnel of the same type and grade according
to government salary scales.
Capital costs included buildings, equipment, vehicles, and
furniture. An inventory list of equipments and furniture and
the size of buildings was established for all departments/units.
Capital items were valued at replacement cost: the price of
equipment, furniture and vehicles was obtained from local
suppliers (market prices), whereas the replacement cost of
buildings was based on the rental price per square meter of
office space in the area. Capital costs were annualized using a
discount rate of 10%, which is the rate mostly used for project
appraisals in Africa. A discount rate of 0% (i.e. straight-line
depreciation) and standard rates of 3% and 5%27,28 were used
in the sensitivity analysis. We assumed a lifespan of 30 years
for buildings, 10 years for equipment and furniture, and
5 years for vehicles.
The step-down costing was applied as described by Conteh
andWalker29 using an adapted version of theWHO-CHOICE‡
CostIt software package for estimating hospital unit costs.
Briefly described, the various departments/units at each health
facility were divided into direct and indirect cost centers.
Direct costs centers provided services directly to the patient
(e.g., outpatient unit or wards), whereas indirect cost centers
provided general services that are necessary to run a hospital,
but were not directly related to patient care such as the admin-
istration or maintenance department. The final (direct) cost
center of interest to this study was the inpatient ward (all
wards were grouped together).§ In a first step, we allocated
costs directly to the inpatient ward when resource usage could
be identified. This was for instance the case with personnel
costs whereby medical staff were assigned a proportion of their
time (and thus cost) to the inpatient ward based on interviews
with the staff. Other costs that could not be assigned directly to
the inpatient ward were allocated on the basis of criteria
reflecting service use including floor space (for costs of main-
tenance, cleaning, and utilities) and number of staff (for the
administration costs).
Once all costs had been assigned to the inpatient ward, a
unit cost per inpatient day was calculated by dividing the total
cost of the inpatient ward with the total number of inpatient
bed-days. Information about the number of inpatient bed-days
at each facility was not readily available and was estimated by
multiplying the number of admissions with the average length
of stay (ALOS). The number of admissions of VL and non-
VL patients was retrieved from the statistical records. The
ALOS of VL patients was 30 days and obtained from the
same sample of 250 medical records described previously.
The ALOS of non-VL patients was estimated by taking a
random sample of 120 medical records at each facility and
recording the date of admission and date of discharge.¶ The
ALOS for non-VL patients ranged from 2 days at Kassab
to 3.5 days at Doka Hospital.
The median total cost of VL care from the provider per-
spective was obtained by multiplying the unit cost per inpa-
tient day with the ALOS for a VL patient and adding to this
figure the medical costs per VL patient obtained with the
ingredients approach.
Costs from the household perspective. Costs from the house-
hold perspective, included direct and indirect costs. These were
collected with a hospital exit survey using a pre-tested struc-
tured questionnaire. A total of 75 patients were interviewed at
Kassab Hospital (N = 45) and Bazora hospital (N = 30) between
December 2010 andMay 2011. At the time of the survey there
were no patients attending Doka Hospital because of a short-
age of SSG at the hospital. The interviews were conducted in
Arabic by a medical doctor with extensive experience in VL
diagnosis and treatment (one of the authors, AA).
The monetary expenditures by patients and their family to
access and receive VL services were recorded separately for
all health care providers that were visited. Respondents were
asked about all direct medical costs they incurred such as
expenditure on registration fees, drugs, laboratory investiga-
tions, and medical supplies at each provider. The survey also
included questions on non-medical costs including the cost of
transportation to and from the various health providers and
food costs incurred while traveling to a health provider and
during hospitalization at the treatment facility.
Indirect costs represented the loss of productive time of
patients and family members taking care of the patient caused
by VL illness. Patients and their caretakers were asked about
§None of the health facilities had disease-specific wards but were
differentiated by gender and age (male, female and pediatric ward).
¶At Kassab, all medical records of non-VL patients were consulted.
‡World Health Organization, Choosing Interventions that are Cost
Effective (WHO-CHOICE): http://www.who.int/choice/toolkit/cost_it/
en/index.html.
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the number of days they were unable to engage in productive
activities, and this was multiplied by a median daily income to
obtain the indirect cost of a VL episode. Most patients and
caretakers that contributed to the household income com-
bined subsistence farming with casual labor during the off-
season when there was no field work. To estimate the median
daily income (and household income in general), the survey
collected data on the economic activities of all household
members, the number of months these activities were done,
and the daily or monthly income in the case of casual labor.
For subsistence farming, information was collected on the
annual production of each produce, which was valued with
local market prices and divided by the number of agricultur-
ally active household members. Data were also gathered on
the income from sales of animals and animal products (e.g.,
milk) and remittances from family members. Farming activi-
ties were done on average 6 months per year, whereas the rest
of the year consisted of casual labor usually in construction
(e.g., brick making) or the collection and sale of wood.
The direct and indirect costs were added together to
obtain the median total cost of an episode of VL from the
perspective of the household. The costs of VL were consid-
ered catastrophic if they exceeded 10% of the annual house-
hold income.30,31
Data analysis. The data were entered into Excel (Microsoft
Corp., Redmond, WA) and analyzed with Excel and STATA
v10.1 (Stata Corp., College Station, TX). Cost data collected
before 2010 were inflated using the consumer price index32
to the year 2010. All cost data are presented in US$ whereby
US$1 = SDP 2.64 (2010).
RESULTS
Costs from the provider perspective. Table 2 shows the
median cost of VL case management per patient from the
provider perspective and activity data for each of the three
health facilities. The total cost includes both the “hotel” and
the medical component.
There were marked differences in the median total cost
per patient between facilities ranging from US$117 at Bazora,
US$155 at Kassab, and US$366 at Doka Hospital. The medi-
cal cost of VL represented 13%, 30%, and 38% of total costs
at Doka, Kassab, and Bazora, respectively. The median med-
ical cost was US$45 (interquartile range [IQR] US$28–75) per
patient with the cost of SSG representing 91% of medical
costs. The large variation between facilities in the total cost
per patient was caused by the difference in the (hotel) unit
cost per inpatient day. Although the unit cost per inpatient
day was similar at Bazora and Kassab Hospitals (US$2.5 and
US$3.8, respectively), it was nearly three times higher at
Doka Hospital compared with Kassab (US$11/inpatient day).
Varying the discount rate between 0% and 10% did not
have much impact on the cost per inpatient day. At Bazora
Hospital, where capital costs as a proportion of total hospital
costs were the largest (23% versus 12% at Kassab and 11% at
Doka), the unit cost per inpatient day changed from US$2.1
(0% discount rate) to US$2.5 (10% discount rate).
Costs from the household perspective. Patient and house-
hold characteristics. A total of 75 patients attending Kassab
(N = 45) and Bazora Hospital (N = 30) were interviewed; we
did not interview any patients at Doka Hospital because of a
shortage of VL drugs at the time of the study. The cost data
from the household perspective collected from Kassab and
Bazora Hospitals were combined in the analysis (Tables 3
and 4). Site-specific household cost data are provided in
Appendix 1.
The majority of patients were males (68.0%) and young
with 60% of patients of < 15 years of age corresponding to
the age profile of other studies showing the epidemic in East
Africa is concentrated amount the young. The median age of
the sample was 13 (range 3–40); female patients were younger
than males (median 7.5 [range 2–34] versus 13 [range 2–40];
P < 0.05). Overall the level of education was low. Among
patients 6 years of age and above (N = 61), 29 (47.5%)
had not received any formal education (including Koranic
schools). Only three patients had completed primary school.
There were major differences in the level of education
between males and females whereby male patients were more
likely to have received some primary education (P < 0.01).
The median household size was six members.
Twenty-nine per cent of patients were economically active
(N = 22), mainly engaged in subsistence farming (N = 13;
59.1%) and daily labor (N = 7; 31.9%). Two patients were
formally employed. Of those engaged in farming, seven
patients were working as casual laborers during the off-season
(defined as secondary occupation). The median annual income
of working patients was US$471 (IQR US$244–1,049).
Subsistence farming was the principal economic activity for
80% of households (N = 60). A median of two different crops
were cultivated by the same household (IQR 2–3; range 1–4);
sorghum was the most common crop, followed by sesame,
millet, and peanuts. Although 40% of households reported
owning livestock, either sheep, goats, and/or cattle, the
headcount was low and only 47% of these households sold
livestock over the past year (N = 14) contributing to 6% of
their household income. About 19% of households reported
receiving remittances, nearly all from outside Sudan (92.9%).
The median amount of remittances received was US$378
Table 2
Activity statistics and unit costs by health facility
Area covered
Kassab Hospital Doka Hospital Bazora Hospital
Between Rahad and Atbara Rivers Between Rahad and Atbara Rivers Rahad River Basin
Beds 68 82 51
Admissions VL (non-VL) 805 (95) 102 (3,049) 580 (1,198)
In-patient days VL (non-VL) 24,150 (187) 3,060 (10,641) 17,400 (3,810)
Total in-patient days 24,337 13,701 21,210
Average length-of-stay VL (non-VL)* 30 (2) 30 (3.5) 30 (3)
Bed occupancy rate 111% 46% 114%
Median cost per patient (IQR) (US$) 154 (137–186) 366 (349–399) 117 (100–147)
*The ALOS was estimated from a random sample of medical records of visceral leishmaniasis (VL) and non-VL patients.
THE COST OF VISCERAL LEISHMANIASIS IN SUDAN 1149
per year (IQR US$114–454). Including all sources of income,
the median annual household income was US$1,116 (IQR
US$744–1,818) and the median annual per capita income
was US$208 (IQR US$140–341).
Direct costs at health providers before admission. Before
admission for treatment at Kassab or Bazora Hospitals,
patients had visited on average three other health providers
(IQR 2–4). A public provider—either a village health worker
(43%), a health center (20%), or a hospital (25%)—was most
often the first choice of provider mainly because of their
proximity to the patients’ home, whereas the remainder of
patients visited either a chemist (3%) or a private general
practitioner (9%). Because there are few private (formal)
health providers in rural areas, < 10% of households had
initially visited a private provider. In subsequent visits, house-
holds consulted a private general practitioner more frequently
(24% of households had consulted a private general practi-
tioner after the first provider) or a public hospital until even-
tually all patients consulted were referred to either Kassab or
Bazora Hospitals and admitted for treatment.
Households incurred a median total cost of US$33 during
the health-seeking phase (IQR US$9–73) (Table 3) and this
included expenses on consultation (US$1), drugs (US$14),
laboratory investigations (US$3), and transportation (US$1)
(Table 4). Households paid the most at private formal pro-
viders (US$51), twice as much as at public hospitals (US$24)
(P < 0.01), of which 94% were direct medical costs for consul-
tation, drugs, and diagnosis/laboratory investigations. House-
holds that visited private laboratories were usually referred by
a previous provider to be tested for VL.
Direct costs at the treatment facility. The combined direct
medical and non-medical costs by households for Kassab and
Bazora Hospital are presented in Table 4. All interviewed
patients were treated with SSG; our study confirmed that
SSG was provided free of charge to patients in these two
facilities. Very few laboratory investigations were done once
the patient was admitted. The median direct medical cost was
US$14 (IQRUS$10–22). Over 85% of costs were non-medical,
mainly food costs (median US$112) caused by the long stay at
the hospital (median 30 days). The food costs were for the
patient, caretaker(s), and other accompanying relatives. All
patients were accompanied by at least one adult caretaker,
usually the mother, and one or two young children that stayed
with the patient at the hospital for the full duration of treat-
ment. The median direct cost of VL care at the treatment
facility was US$148 (IQR US$128–184).
Indirect costs of VL. Sixteen out of 22 patients (73%)
reported they were unable to carry out either their primary
or secondary occupation because of VL illness, which resulted
in an income loss. The median number of workdays lost was
51 days (IQR 44–63). The median loss of income for working
patients was US$101 (IQR US$62–233), whereas the average
loss of income across all patients was US$41 (SD US$135).
Among adult caretakers, 20 reported an income loss (out
of 99 caretakers), with a median loss of 39 working days
(IQR 31–58) because they had to take care of the patient.
The median loss of income to caretakers was US$95
(IQR US$45–179). The average income loss across all atten-
dants, both working and non-working was US$44 (SD US$85).
Total costs of a VL episode. The median total cost for
one VL episode was US$450 (IQR US$387–544) (Table 5).
The median cost of VL case management across the three
health facilities was US$211 (IQR US$197–244). The median
direct expenditure by households, including the health-seeking
phase and the costs incurred at the treatment facility, was
US$185 (IQR US$158–240), whereas the median income loss
(i.e., indirect costs) was US$22 (IQR US$0–113.9). Overall,
households bore 53% of the total cost of VL and public
health facilities 47%. Direct costs, in particular non-medical
costs, were the main cost driver from the perspective of the
household representing nearly 86% of the median household
cost, whereas indirect costs represented 14% of this cost.
The median annual household income was estimated to
be US$1,116. The economic burden of VL to households,
Table 4
Mean/median direct costs of visceral leishmaniasis (VL) care during the health-seeking and treatment phase (US$ 2010)
Health-seeking phase Admission and treatment
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Direct medical costs
Consultation 6.6 (13.0) 1.1 (0.0–6.0) 3.3 (1.7) 3.7 (1.1–4.8)
Ancillary drugs 26.0 (47.7) 13.8 (6.7–37.2) 11.1 (10.0) 7.4 (4.3–15.6)
Laboratory investigations 13.2 (24.9) 3.3 (0.0–16.7) 4.1 (7.0) 1.9 (0.2–4.1)
Total direct medical costs 45.9 (78.4) 24.2 (9.3-54.0) 18.5 (14.9) 14.0 (9.9–22.3)
Direct non-medical costs
Transportation 7.5 (14.7) 1.1 (0.0–7.4) 6.5 (10.1) 2.6 (0.7–8.9)
Food 6.5 (19.9) 0.0 (0.0–4.8) 121.5 (44.5) 111.6 (111.6–141.4)
Other 1.0 (4.4) 0.0 (0.0–0.2) 5.0 (4.1) 4.5 (2.0–6.9)
Total direct non-medical costs 15.0 (31.1) 2.6 (0.0–18.6) 133 (46.0) 126.5 (113.9–157.8)
Total direct costs 60.8 (103.5) 33.1 (9.3–73.3) 151.5 (49.1) 148.5 (128.2–184.2)
Note: All data presented in this table was calculated using data collected at two hospitals (Kassab and Bazora). Household costs by facility are provided in Supplemental Appendix Tables A.2
and A.3.
Table 3
Mean/median cost per provider visited during the health seeking
phase prior to admission (US$ 2010)
Health provider n Mean (SD) Median (IQR)
Traditional healer 3 10.2 (9.2) 10.2 (3.7–16.7)
Chemist 2 8.7 (4.5) 8.7 (5.6–11.9)
Village health worker 37 14.6 (19.8) 9.3 (4.5–16.0)
Public health center 22 33.3 (44.7) 15.3 (10.0–42.8)
Public hospital 30 56.8 (73.8) 24.2 (12.1–55.8)
Private doctor 26 90.7 (125.4) 51.2 (32.7–101.2)
Private laboratory 13 27.9 (16.8) 26.0 (17.9–34.2)
Total cost per person 75 60.8 (103.5) 33.1 (9.3–73.3)
Note: All data presented in this table was calculated using data collected at two hospitals
(Kassab and Bazora). Household costs by facility are provided in Supplemental Appendix
Table A.1.
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including direct and indirect costs, was equal to 23% of the
median annual household income.
DISCUSSION
This is the first study to provide a comprehensive set of
estimates on the cost and economic burden of VL in Sudan
and East Africa in general. We collected data from both the
provider and the household perspective. Data on provider
costs were collected from three health facilities in Gedaref
State; direct costs to access treatment and indirect costs of
VL illness from the perspective of the household were col-
lected using a structured exit questionnaire with 75 patients in
two of these facilities.
The median total cost per episode of VL was estimated to
be US$450. Over 75% of households incurred catastrophic
out-of-pocket expenditures (defined as expenditures exceed-
ing 10% of annual median income) when considering only
direct costs, whereas 83% of households exceeded this thresh-
old when also including indirect costs. These findings concur
with studies that were carried out in the Indian subcontinent
(Nepal, India, and Bangladesh), which also found a huge
economic burden of VL illness for households.2,4,33–35 There
were however some differences with regard to the distribution
of costs. Indirect cost as a proportion of the total household
cost was smaller in Sudan, mainly linked with a different age
profile. In our study we found that 60% of patients were
below the age of 15, although in Bangladesh, for instance, it
was 47%3; these differences are consistent with the demo-
graphic profile of VL across countries reported by Harhay
and others.36 Because patients were younger in Sudan, fewer
reported earning an income. For instance, we found that 29%
of patients were economically active and generating an
income to the household compared with 36% in Nepal
(Uranw and others, unpublished data) and 42% in India.2
In terms of the provider costs, the cost of hospitalization
(which did not include the medical costs of VL) was the main
cost driver and varied between 62% and 87% of the total
provider cost at Bazora and Doka Hospitals, respectively.
We observed large differences in the unit cost per inpatient
day across the three facilities. There are several factors that
explain the higher unit cost per inpatient day at Doka Hospital.
From the cost side, because Doka Hospital is a secondary
level referral facility, it has more skilled health staff resulting
in higher personnel costs. For instance the ratio of medical
doctors working at Doka compared with Bazora Hospital was
5:1. The capital costs were also higher compared with the other
two health facilities. However, the factor that influenced the
unit cost most was the workload at each hospital, and in
particular the number of VL patients. Because most costs are
fixed (including personnel costs on the short and medium
term) and do not vary with the number of inpatients at the
hospital, the fewer the inpatients, the higher the unit cost per
inpatient day. A total of 1,487 patients were admitted for VL
treatment in the three study facilities in 2008, with important
differences in case load across facilities. Overall, the bed
occupancyk rate at Doka Hospital was low (46%), whereas
in Kassab and Bazora it exceeded 100% (on average, there
were not sufficient beds to accommodate all patients). Doka
Hospital admitted the least VL patients in 2008 as a result of
frequent shortages of SSG. These patients were then referred
to Kassab Hospital, located ~50 kms away. The number of
VL patients at Bazora Hospital was high because the hospital
covers a very large area (the Rahad River Basin) with impor-
tant transmission of VL.
Our estimates were also lower than the WHO-CHOICE
hotel unit cost estimates for Sudan (i.e., US$13.5 inflation-
adjusted for a secondary-level hospital at 80% occupancy
rate).26 The variation in unit costs between facilities in this
study was caused by differences in the cost structure of the
health facilities, but especially by the patient load because we
observed a low occupancy rate at Doka Hospital (46%) and
rates exceeding full occupancy at Kassab and Bazora. During
the time of the study, most VL patients who attended Doka
Hospital were referred to Kassab Hospital because of a short-
age in SSG drugs. Given these logistical problems the unit
costs of hospitalization should be interpreted with care and
not considered as an indicator of efficient resource usage. As
Hansen and others21 noted in a study on the hospital costs of
HIV/acquired immunodeficiency syndrome (AIDS) care, low
unit costs may also indicate insufficient resources at these
health facilities. Although an evaluation of optimal resource
usage for VL care and other services was not within the scope
of this study, there were clear indications that for example the
hospital in Bazora was under-staffed compared with its
patient load.
A limitation to our study was that we did not capture the
seasonal pattern of costs. Although this is less relevant for
provider costs that were based on data for a complete finan-
cial year, the household survey was carried out half-way
through the dry season, which takes place approximately from
November to April. This may have had an impact on the
health-seeking behavior of households and transportation
costs. Because health facilities are more accessible during the
dry season, patients are likely to present faster to a health
facility and transportation costs will be lower. For example,
Gerstl and others37 in a study examining the accessibility of
VL treatment centers in Gedaref State found that transporta-
tion costs were two to three times higher during the rainy
season. In addition, the time of the survey may also have had
an impact on the opportunity cost of time lost caused by VL
illness and treatment. Patients involved in subsistence farming
reported they were not working at the time of the survey
kThe bed occupancy rate was calculated as the number of inpatient
days in a year divided by the number of beds + 365.
Table 5
Summary of direct and indirect costs for one visceral leishmaniasis
(VL) episode (US$ 2010)
Mean (SD) Median (IQR)
Direct costs
Household* 212.4 (122.8) 185.1 (158.5–240.2)
Provider† 220.3 (31.4) 211.1 (197.3–243.9)
Indirect costs 118.8 (181.9) 22.3 (0–113.9)
Total cost
Household 297.1 (250.4) 238.4 (171.8–333.2)
Household + provider 508.2 (250.3) 450.0 (386.9–544.3)
Median costs as a % of:
Annual household income 23%
Annual per capita income 122%
*Health-seeking and treatment facility costs; calculated using the mean/median data from
two hospitals (Kassab and Bazora) because no patients attended Doka Hospital at the time
of the study.
†Calculated using the average hotel unit cost of US$5.74 across the three hospitals.
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because it was the off-season. As such, we may have under-
estimated the indirect cost of VL illness for those patients that
did not have a secondary occupation.
Second, data on costs were based on actual consumption
of resources with the major cost elements (medical costs
and personnel) obtained through micro-costing. However,
the hospital records on activity statistics were poor and the
unit costs per inpatient day are particularly sensitive to inac-
curate activity data. Information on the number of admissions
for both VL and non-VL patients were available at each facil-
ity, but the average length of stay needed to be extrapolated
from a random sample of medical records. Although the aver-
age length of stay for VL patients is no doubt close to 30 days
because of the duration of the drug regimen, there was more
uncertainty regarding the ALOS of non-VL patients.
Finally, we were not able to obtain data for all cost catego-
ries at each hospital included in the study. From the provider
perspective, detailed information from medical records to
estimate the direct medical costs was only available at Kassab
Hospital. Data from the household perspective were collected
from Kassab and Bazora Hospitals and not Doka Hospital
because there were no patients attending the latter facility at
the time of the study as a result of a shortage of SSG. Given
the limitations in data availability and because the aim of the
study was to estimate the cost of providing and accessing VL
diagnosis and treatment services, rather than making compar-
isons across facilities (in terms of e.g., efficiency or access),
results were presented in terms of the mean/median across the
three facilities. This is the first study of its kind for VL carried
out in Sudan (and eastern Africa in general). We hope that
in the future, cost data on VL diagnosis and treatment will
be more readily available to support on-going control efforts
in the country.
In the absence of a vaccine and preventive interventions,
the diagnosis and treatment of VL is currently the main con-
trol strategy available in Sudan. We showed VL diagnosis and
treatment to be expensive not only to the public health sector
but also to the households compared with their income. Poli-
cies are therefore needed that reduce this cost to both pro-
viders and households. A common determinant of costs for
both perspectives was the length of treatment. The current
first line treatment is SSG and patients are admitted for the
full duration of treatment of 30 days to ensure adherence to
treatment and monitor for possible side-effects. In recent
years there have been a number of therapeutic innovations
that open the door to treatment alternatives with shorter
duration. These treatment alternatives would not only reduce
the cost of hospitalization from the provider perspective but
also the substantial food costs patients and caretakers incur.
One of the alternatives is a combination of SSG and
paromomycin for 17 days15 that showed an acceptable safety
and efficacy profile in a recent randomized-controlled trial16;
this treatment is in fact now being rolled out in Gedaref state.
Other alternatives include combinations of an oral drug
miltefosine with either SSG or liposomal amphotericin B17
that may reduce treatment to 10 days (for the latter combina-
tion) or a multi-dose regimen of liposomal Amphotericin B
for 10 days.38 Liposomal Amphotericin B (AmBisome) is
already registered in Sudan and used as second-line treatment
but is not considered as first line because of its very high cost
despite preferential pricing agreements between the WHO
and its manufacturer Gilead Sciences (US$270 for total dose
of 21 mg/kg for a 35 kg patient). However, a donation by
Gilead to treat 50,000 patients opens new perspectives for
using AmBisome as the first-line treatment in East Africa.39
The cost data that we presented here will facilitate the use
of cost-effectiveness analysis to compare the various treat-
ment alternatives presently available or in the near future for
Sudan. This study highlighted the importance of including the
household perspective in such analysis because VL caused
catastrophic health expenditure in almost all households
despite drugs and diagnostics being free. In the absence of
effective prevention, the best way to alleviate this burden is
through a treatment regimen with shorter duration. The arti-
cle is hopefully the first in a series of studies investigating the
behavioral and socio-economic aspects of VL and its control.
Until we are able to close this knowledge gap, there will be
little interest from the government and the international com-
munity to actively engage in the control of VL in Sudan and
East Africa in general.
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